Scientific Publications

Publications Medical Meetings

Epitope Discovery for Genomes (EDGE™) Platform

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Nature Biotechnology (Dec 2018)

GRANITE (Individualized Neoantigen Program) Phase 1/2 Study

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.

Nature Medicine (Aug 2022)

SLATE (“Off-the-shelf” Neoantigen Program) Phase 1/2 Study

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results

NATURE MEDICINE (MARCH 2024)

CORAL (COVID-19 Program) Preclinical Study

Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.

Nature Communications (June 2022)

CORAL-BOOST (COVID-19) Phase 1 Study

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.

NATURE COMMUNICATIONS (JUNE 2023)

AI platform provides an EDGE and enables state-of-the-art identification of peptide-HLAs for the development of T cell inducing vaccines and beyond

AACR 2024 (ABSTRACT 7394)

Durable Immune Response Induced by Self-amplifying mRNA (samRNA) SARS-CoV-2 Vaccine Candidates in Vaccine-naïve HIV Negative and People Living with HIV (PLWH) Populations

IDWEEK 2023 (ABSTRACT 1538194)

Durable Immune Response Induced by a Self-amplifying mRNA (samRNA) SARS-CoV-2 Vaccine Candidate in Adults Previously Vaccinated with mRNA or Adenovirus Primary Series

IDWEEK 2023 (ABSTRACT 1538028)

An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults

IDWEEK 2023 (ABSTRACT 1530224)

Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine

AMERICAN ASSOCIATION FOR CANCER RESEARCH 2023 (AACR 2023, ABSTRACT 1126)

Class II-restricted CD4+ T cell responses to KRAS G12C in healthy donors linked to bacterial mimotope: Lessons for KRAS neoantigen vaccines in cancer patients

AMERICAN ASSOCIATION FOR CANCER RESEARCH 2023 (AACR 2023, ABSTRACT 2267)

Language modeling of peptide-HLA interactions achieves state-of-the-art performance on prediction of peptide presentation by HLA Class II

AMERICAN ASSOCIATION FOR CANCER RESEARCH 2023 (AACR 2023, ABSTRACT 5364)

Study of Self-amplifying mRNA (samRNA) Vaccine Candidates Against COVID-19 in Healthy Adults and People Living with Human Immunodeficiency Virus (HIV) in South Africa

33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023, ABSTRACT 03190)

First study of a Self-amplifying mRNA (samRNA) Vaccine, GRT-R910, as a Booster against COVID-19 in Healthy Volunteers ≥60 Years of Age – Preliminary Evidence of Durable Immunity

33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023, ABSTRACT 03157)

Clinicopathologic Characteristics of Patients with Metastatic Colorectal Cancer with Molecular Responses Following Treatment with an Individualized Neoantigen Vaccine Regimen.

Society for Immunotherapy of Cancer 2022 (SITC 2022: abstract 660)

Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS).

European Society for Medical Oncology 2022 (ESMO 2022, abstract 736MO)

Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).

American Society for Clinical Oncology 2022 (ASCO 2022, abstract TPSS3635)

Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients.

American Association for Cancer Research 2022 (AACR 2022, abstract 1238)

Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8+ T cell responses in cancer patients versus high doses.

American Association for Cancer Research 2022 (AACR 2022, abstract 4149)

Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back.

American Association for Cancer Research 2022 (AACR 2022, abstract 3578)

MHC class II antigen identification for cancer immunotherapy by deep learning on tumor HLA peptides.

American Association for Cancer Research 2019 (AACR 2019, abstract 4445)

Identification and Validation of Shared Neoantigens for Cancer Immunotherapy.

Society for Immunotherapy of Cancer 2019 (SITC 2019: abstract P731)

A novel heterologous prime boost vaccine system drives tumor specific and potent CD8 T cell responses for cancer immunotherapy.

American Association for Cancer Research 2018 (AACR 2018, abstract 724)

Antigen identification for cancer immunotherapy by deep learning on tumor HLA peptides.

American Association for Cancer Research 2018 (AACR 2018, abstract 5722)